The Schwab U.S. Dividend Equity ETF (SCHD) is trading just shy of its all-time high, propelled by a record $17.7 billion in year-to-date inflows. As of August 24, the fund was at $35.17, down 0.4% from its 52-week peak, with volume exceeding 20.1 million shares.
The surge in demand has elevated SCHD to a top-performing investment in 2026, with a total return of 27.8% year-to-date, outpacing the Invesco QQQ Trust (QQQ) by 10.7 percentage points and the SPDR S&P 500 ETF (SPY) by 15 points. This performance underscores a broader market shift toward cash-generating, lower-multiple companies.
Inflows and Valuation
By August 14, SCHD had attracted $17.68 billion in net inflows, representing 16.2% of its total assets. This figure surpasses the dollar inflows of QQQ ($15.23 billion) and SPY ($21.03 billion) relative to their asset bases. The fund's expense ratio remains low at 0.06%, making it an attractive option for income-focused investors.
However, the valuation is no longer distressed. SCHD trades at 18.7 times earnings, which, while below many growth portfolios, suggests the value positioning is becoming crowded. New investors are entering at levels near the record high, raising questions about future upside.
Sector Concentration and Implications
SCHD's portfolio is heavily weighted toward defensive sectors: health care (20.72%) and consumer staples (20.38%) combine for over 41% of assets, while technology accounts for just 9.23%. This concentration has been a driver of its 2026 resilience but also exposes investors to sector-specific risks, such as policy uncertainty in health care or commodity price declines in energy (14.07%).
The top 10 holdings represent 41.38% of the portfolio, with significant positions in Merck (MRK), Abbott Laboratories (ABT), Amgen (AMGN), Coca-Cola (KO), and Home Depot (HD). Analyst consensus remains bullish on these names, though price targets imply limited upside for Merck and Amgen, and modest gains for Abbott and Coca-Cola.
Pairing Strategies
Given SCHD's growth shortfall, financial advisors often recommend pairing it with a growth-oriented ETF. A combination with QQQ adds the essential growth element but introduces tech-heavy valuation risk. Alternatively, SPY offers broader diversification, while the Vanguard High Dividend Yield ETF (VYM) provides a similar income profile with less concentration.
The choice depends on the investor's objective. Those seeking style diversification may opt for QQQ in controlled amounts, while those prioritizing broad market exposure might prefer a core fund like SPY, accepting reduced income.
Market Outlook and Risks
Key levels to watch include SCHD's all-time high of $35.31. A sustained move above this level would signal continued demand, while a slowdown in inflows may indicate that much of 2026's rerating is already priced in.
Risks include underperformance if the market is driven by technology gains, rising bond yields dampening interest in dividend funds, and adverse developments in pharmaceuticals, commodity prices, or consumer spending that could impact SCHD's major sector exposures.
